ZA200306410B - New medical uses of intercellular communication facilitating compounds - Google Patents

Info

Publication number

ZA200306410B

ZA200306410B ZA200306410A ZA200306410A ZA200306410B ZA 200306410 B ZA200306410 B ZA 200306410B ZA 200306410 A ZA200306410 A ZA 200306410A ZA 200306410 A ZA200306410 A ZA 200306410A ZA 200306410 B ZA200306410 B ZA 200306410B

Authority

ZA

South Africa

Prior art keywords

sar

gly

ala

pro

compound

Prior art date

2000-02-23

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 293
• 230000035992 intercellular communication Effects 0.000 title claims description 70
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 97
• -1 aralkyl ester Chemical class 0.000 claims abstract description 69
• 150000003839 salts Chemical class 0.000 claims abstract description 44
• 125000000539 amino acid group Chemical group 0.000 claims abstract description 30
• 125000000217 alkyl group Chemical group 0.000 claims abstract description 27
• 125000003118 aryl group Chemical group 0.000 claims abstract description 24
• 125000004122 cyclic group Chemical group 0.000 claims abstract description 17
• 150000001408 amides Chemical class 0.000 claims abstract description 16
• 125000001424 substituent group Chemical group 0.000 claims abstract description 12
• 210000004027 cell Anatomy 0.000 claims description 290
• 210000003976 gap junction Anatomy 0.000 claims description 238
• 108050001175 Connexin Proteins 0.000 claims description 203
• 102000010970 Connexin Human genes 0.000 claims description 201
• 238000011282 treatment Methods 0.000 claims description 109
• 230000000694 effects Effects 0.000 claims description 83
• 239000003814 drug Substances 0.000 claims description 81
• 210000001519 tissue Anatomy 0.000 claims description 77
• 230000008878 coupling Effects 0.000 claims description 75
• 238000010168 coupling process Methods 0.000 claims description 75
• 238000005859 coupling reaction Methods 0.000 claims description 75
• 238000002360 preparation method Methods 0.000 claims description 74
• 238000004891 communication Methods 0.000 claims description 73
• 230000006854 communication Effects 0.000 claims description 73
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 56
• 230000001965 increasing effect Effects 0.000 claims description 50
• 201000010099 disease Diseases 0.000 claims description 49
• 210000002216 heart Anatomy 0.000 claims description 47
• 208000027418 Wounds and injury Diseases 0.000 claims description 42
• 206010028980 Neoplasm Diseases 0.000 claims description 38
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 36
• 206010047302 ventricular tachycardia Diseases 0.000 claims description 36
• 230000001771 impaired effect Effects 0.000 claims description 35
• 229910052760 oxygen Inorganic materials 0.000 claims description 35
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 34
• 239000008103 glucose Substances 0.000 claims description 34
• 208000028867 ischemia Diseases 0.000 claims description 33
• 230000002265 prevention Effects 0.000 claims description 33
• 108010075130 AAP 10 Proteins 0.000 claims description 30
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
• 150000001413 amino acids Chemical class 0.000 claims description 29
• 206010003119 arrhythmia Diseases 0.000 claims description 29
• 230000003247 decreasing effect Effects 0.000 claims description 29
• 229910052736 halogen Inorganic materials 0.000 claims description 29
• 150000002367 halogens Chemical group 0.000 claims description 29
• 229910052739 hydrogen Inorganic materials 0.000 claims description 28
• 230000006793 arrhythmia Effects 0.000 claims description 27
• 230000015572 biosynthetic process Effects 0.000 claims description 26
• 206010052428 Wound Diseases 0.000 claims description 25
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 24
• 239000001301 oxygen Substances 0.000 claims description 24
• 230000002792 vascular Effects 0.000 claims description 22
• 230000006378 damage Effects 0.000 claims description 21
• 230000002829 reductive effect Effects 0.000 claims description 20
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
• 201000011510 cancer Diseases 0.000 claims description 18
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
• 230000002861 ventricular Effects 0.000 claims description 18
• 108010082685 antiarrhythmic peptide Proteins 0.000 claims description 17
• 208000014674 injury Diseases 0.000 claims description 17
• 238000003786 synthesis reaction Methods 0.000 claims description 17
• 230000035876 healing Effects 0.000 claims description 15
• 230000006698 induction Effects 0.000 claims description 15
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 14
• 206010012601 diabetes mellitus Diseases 0.000 claims description 12
• 230000012010 growth Effects 0.000 claims description 12
• 230000004054 inflammatory process Effects 0.000 claims description 12
• 210000003932 urinary bladder Anatomy 0.000 claims description 12
• 206010061218 Inflammation Diseases 0.000 claims description 11
• 210000000988 bone and bone Anatomy 0.000 claims description 11
• 210000004556 brain Anatomy 0.000 claims description 11
• 210000003169 central nervous system Anatomy 0.000 claims description 11
• 230000001419 dependent effect Effects 0.000 claims description 11
• 238000011161 development Methods 0.000 claims description 11
• 230000018109 developmental process Effects 0.000 claims description 11
• 239000001257 hydrogen Substances 0.000 claims description 11
• 150000002500 ions Chemical class 0.000 claims description 11
• 230000006609 metabolic stress Effects 0.000 claims description 11
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
• 208000001132 Osteoporosis Diseases 0.000 claims description 10
• 206010033645 Pancreatitis Diseases 0.000 claims description 10
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 10
• ATCGGEJZONJOCL-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 ATCGGEJZONJOCL-UHFFFAOYSA-N 0.000 claims description 9
• OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 9
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 9
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 9
• 230000002496 gastric effect Effects 0.000 claims description 9
• 229940088597 hormone Drugs 0.000 claims description 9
• 239000005556 hormone Substances 0.000 claims description 9
• 238000002347 injection Methods 0.000 claims description 9
• 239000007924 injection Substances 0.000 claims description 9
• 229950010984 irsogladine Drugs 0.000 claims description 9
• YQAXFVHNHSPUPO-RNJOBUHISA-N 2-[[(2s)-2-[[2-[[(2s,4r)-1-[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H]1N(C(=O)CN)CCC1 YQAXFVHNHSPUPO-RNJOBUHISA-N 0.000 claims description 8
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 8
• 208000002177 Cataract Diseases 0.000 claims description 8
• 206010020772 Hypertension Diseases 0.000 claims description 8
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 8
• 208000007107 Stomach Ulcer Diseases 0.000 claims description 8
• 210000004899 c-terminal region Anatomy 0.000 claims description 8
• 229910052731 fluorine Inorganic materials 0.000 claims description 8
• 208000015181 infectious disease Diseases 0.000 claims description 8
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 7
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
• 208000025865 Ulcer Diseases 0.000 claims description 7
• 238000003556 assay Methods 0.000 claims description 7
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
• 208000035475 disorder Diseases 0.000 claims description 7
• 229910052740 iodine Inorganic materials 0.000 claims description 7
• 239000000203 mixture Substances 0.000 claims description 7
• 231100000397 ulcer Toxicity 0.000 claims description 7
• 206010011878 Deafness Diseases 0.000 claims description 6
• 239000000556 agonist Substances 0.000 claims description 6
• 206010003246 arthritis Diseases 0.000 claims description 6
• 230000001746 atrial effect Effects 0.000 claims description 6
• 229910052794 bromium Inorganic materials 0.000 claims description 6
• 210000003477 cochlea Anatomy 0.000 claims description 6
• 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
• UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 6
• 210000000981 epithelium Anatomy 0.000 claims description 6
• 229930195729 fatty acid Natural products 0.000 claims description 6
• 239000000194 fatty acid Substances 0.000 claims description 6
• 150000004665 fatty acids Chemical class 0.000 claims description 6
• 208000016354 hearing loss disease Diseases 0.000 claims description 6
• 230000006872 improvement Effects 0.000 claims description 6
• 230000001537 neural effect Effects 0.000 claims description 6
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
• 210000001672 ovary Anatomy 0.000 claims description 6
• 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 5
• 125000003545 alkoxy group Chemical group 0.000 claims description 5
• 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
• 239000001110 calcium chloride Substances 0.000 claims description 5
• 229910001628 calcium chloride Inorganic materials 0.000 claims description 5
• 208000037976 chronic inflammation Diseases 0.000 claims description 5
• 230000006020 chronic inflammation Effects 0.000 claims description 5
• 230000009843 endothelial lesion Effects 0.000 claims description 5
• 230000003394 haemopoietic effect Effects 0.000 claims description 5
• 230000028709 inflammatory response Effects 0.000 claims description 5
• 230000000302 ischemic effect Effects 0.000 claims description 5
• 208000017169 kidney disease Diseases 0.000 claims description 5
• 208000004296 neuralgia Diseases 0.000 claims description 5
• 230000004770 neurodegeneration Effects 0.000 claims description 5
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
• 208000021722 neuropathic pain Diseases 0.000 claims description 5
• 239000008194 pharmaceutical composition Substances 0.000 claims description 5
• 230000028327 secretion Effects 0.000 claims description 5
• 229910052717 sulfur Inorganic materials 0.000 claims description 5
• 208000010228 Erectile Dysfunction Diseases 0.000 claims description 4
• 208000007984 Female Infertility Diseases 0.000 claims description 4
• 206010021928 Infertility female Diseases 0.000 claims description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
• 208000028017 Psychotic disease Diseases 0.000 claims description 4
• 208000026062 Tissue disease Diseases 0.000 claims description 4
• 206010046543 Urinary incontinence Diseases 0.000 claims description 4
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
• 210000000845 cartilage Anatomy 0.000 claims description 4
• 229910052801 chlorine Inorganic materials 0.000 claims description 4
• 208000000718 duodenal ulcer Diseases 0.000 claims description 4
• 201000001881 impotence Diseases 0.000 claims description 4
• 230000002458 infectious effect Effects 0.000 claims description 4
• 230000003902 lesion Effects 0.000 claims description 4
• 208000028169 periodontal disease Diseases 0.000 claims description 4
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
• CCUAQNUWXLYFRA-IMJSIDKUSA-N Ala-Asn Chemical compound C[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC(N)=O CCUAQNUWXLYFRA-IMJSIDKUSA-N 0.000 claims description 3
• 208000023275 Autoimmune disease Diseases 0.000 claims description 3
• 235000021357 Behenic acid Nutrition 0.000 claims description 3
• 208000035473 Communicable disease Diseases 0.000 claims description 3
• DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 claims description 3
• ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims description 3
• QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 3
• 208000004547 Hallucinations Diseases 0.000 claims description 3
• 206010019196 Head injury Diseases 0.000 claims description 3
• 208000012659 Joint disease Diseases 0.000 claims description 3
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
• 208000026139 Memory disease Diseases 0.000 claims description 3
• 208000024777 Prion disease Diseases 0.000 claims description 3
• 208000001871 Tachycardia Diseases 0.000 claims description 3
• 125000002252 acyl group Chemical group 0.000 claims description 3
• 230000002785 anti-thrombosis Effects 0.000 claims description 3
• 229940116226 behenic acid Drugs 0.000 claims description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
• 206010027175 memory impairment Diseases 0.000 claims description 3
• 230000004899 motility Effects 0.000 claims description 3
• 235000019260 propionic acid Nutrition 0.000 claims description 3
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 3
• 210000001525 retina Anatomy 0.000 claims description 3
• 210000000278 spinal cord Anatomy 0.000 claims description 3
• 208000020431 spinal cord injury Diseases 0.000 claims description 3
• 230000006794 tachycardia Effects 0.000 claims description 3
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
• 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
• 208000019901 Anxiety disease Diseases 0.000 claims description 2
• 206010065687 Bone loss Diseases 0.000 claims description 2
• 208000007466 Male Infertility Diseases 0.000 claims description 2
• XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 2
• 101800000989 Oxytocin Proteins 0.000 claims description 2
• 208000018737 Parkinson disease Diseases 0.000 claims description 2
• 208000000921 Urge Urinary Incontinence Diseases 0.000 claims description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
• 210000004198 anterior pituitary gland Anatomy 0.000 claims description 2
• 230000036506 anxiety Effects 0.000 claims description 2
• 230000010370 hearing loss Effects 0.000 claims description 2
• 231100000888 hearing loss Toxicity 0.000 claims description 2
• 210000002200 mouth mucosa Anatomy 0.000 claims description 2
• 230000003387 muscular Effects 0.000 claims description 2
• XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 2
• 229960001723 oxytocin Drugs 0.000 claims description 2
• 102000014187 peptide receptors Human genes 0.000 claims description 2
• 230000002062 proliferating effect Effects 0.000 claims description 2
• 230000007480 spreading Effects 0.000 claims description 2
• 238000003892 spreading Methods 0.000 claims description 2
• 206010046494 urge incontinence Diseases 0.000 claims description 2
• 230000006496 vascular abnormality Effects 0.000 claims description 2
• LZJRNLRASBVRRX-ZDUSSCGKSA-N Boldine Chemical compound CN1CCC2=CC(O)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(O)=C1 LZJRNLRASBVRRX-ZDUSSCGKSA-N 0.000 claims 4
• LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 4
• MTAWKURMWOXCEO-UHFFFAOYSA-N taspine Chemical compound O1C(=O)C2=C(CCN(C)C)C=C(OC)C3=C2C2=C1C(OC)=CC=C2C(=O)O3 MTAWKURMWOXCEO-UHFFFAOYSA-N 0.000 claims 4
• QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 3
• 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 claims 3
• 238000010172 mouse model Methods 0.000 claims 3
• 229940016667 resveratrol Drugs 0.000 claims 3
• 235000021283 resveratrol Nutrition 0.000 claims 3
• KYVJVURXKAZJRK-UHFFFAOYSA-N (+)-laurolitsine Natural products N1CCC2=CC(O)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 KYVJVURXKAZJRK-UHFFFAOYSA-N 0.000 claims 2
• 229930013930 alkaloid Natural products 0.000 claims 2
• MHVCSDLBQKSFQV-HNNXBMFYSA-N boldine Natural products COc1cc2c(C[C@@H]3N(C)CCc4cc(C)c(OC)c2c34)cc1O MHVCSDLBQKSFQV-HNNXBMFYSA-N 0.000 claims 2
• LZJRNLRASBVRRX-UHFFFAOYSA-N boldine trifluoroacetic acid salt Natural products CN1CCC2=CC(O)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 LZJRNLRASBVRRX-UHFFFAOYSA-N 0.000 claims 2
• 210000004087 cornea Anatomy 0.000 claims 2
• 239000003085 diluting agent Substances 0.000 claims 2
• 239000003937 drug carrier Substances 0.000 claims 2
• 150000002431 hydrogen Chemical class 0.000 claims 2
• 208000024891 symptom Diseases 0.000 claims 2
• RKEBJJCZAOFMLH-UHFFFAOYSA-N taspine Natural products COc1ccc2OC(=O)c3c(OC)cc(CN(C)C)c4OC(=O)c1c2c34 RKEBJJCZAOFMLH-UHFFFAOYSA-N 0.000 claims 2
• 125000005309 thioalkoxy group Chemical group 0.000 claims 2
• 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
• 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 claims 1
• XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 claims 1
• 208000010392 Bone Fractures Diseases 0.000 claims 1
• 206010005949 Bone cancer Diseases 0.000 claims 1
• 208000018084 Bone neoplasm Diseases 0.000 claims 1
• 201000009030 Carcinoma Diseases 0.000 claims 1
• 208000035484 Cellulite Diseases 0.000 claims 1
• 206010011026 Corneal lesion Diseases 0.000 claims 1
• 206010018338 Glioma Diseases 0.000 claims 1
• 206010018341 Gliosis Diseases 0.000 claims 1
• 206010066476 Haematological malignancy Diseases 0.000 claims 1
• 206010027439 Metal poisoning Diseases 0.000 claims 1
• 241000208125 Nicotiana Species 0.000 claims 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
• 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 claims 1
• 206010049752 Peau d'orange Diseases 0.000 claims 1
• 206010065342 Supraventricular tachyarrhythmia Diseases 0.000 claims 1
• 239000003146 anticoagulant agent Substances 0.000 claims 1
• 208000035269 cancer or benign tumor Diseases 0.000 claims 1
• 206010061592 cardiac fibrillation Diseases 0.000 claims 1
• 230000036232 cellulite Effects 0.000 claims 1
• UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
• 239000000539 dimer Substances 0.000 claims 1
• 230000008482 dysregulation Effects 0.000 claims 1
• 230000002600 fibrillogenic effect Effects 0.000 claims 1
• 230000007387 gliosis Effects 0.000 claims 1
• 208000010501 heavy metal poisoning Diseases 0.000 claims 1
• 230000010262 intracellular communication Effects 0.000 claims 1
• 230000000813 microbial effect Effects 0.000 claims 1
• 201000001119 neuropathy Diseases 0.000 claims 1
• 230000007823 neuropathy Effects 0.000 claims 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
• 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 1
• 208000019899 phobic disease Diseases 0.000 claims 1
• 229920000642 polymer Polymers 0.000 claims 1
• 235000003784 poor nutrition Nutrition 0.000 claims 1
• 230000009759 skin aging Effects 0.000 claims 1
• 238000011476 stem cell transplantation Methods 0.000 claims 1
• 235000018991 trans-resveratrol Nutrition 0.000 claims 1
• 239000013638 trimer Substances 0.000 claims 1
• 239000011800 void material Substances 0.000 claims 1
• 230000037303 wrinkles Effects 0.000 claims 1
• 239000000126 substance Substances 0.000 abstract description 58
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 21
• 125000005647 linker group Chemical group 0.000 abstract description 7
• 125000003710 aryl alkyl group Chemical group 0.000 abstract description 6
• 101800001415 Bri23 peptide Proteins 0.000 abstract description 5
• 102400000107 C-terminal peptide Human genes 0.000 abstract description 5
• 101800000655 C-terminal peptide Proteins 0.000 abstract description 5
• 125000003277 amino group Chemical group 0.000 abstract description 4
• 238000011191 terminal modification Methods 0.000 abstract description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 2
• 101710188315 Protein X Proteins 0.000 abstract description 2
• 229940125782 compound 2 Drugs 0.000 description 95
• 102100021337 Gap junction alpha-1 protein Human genes 0.000 description 92
• 108010069241 Connexin 43 Proteins 0.000 description 91
• 235000013350 formula milk Nutrition 0.000 description 71
• 238000000034 method Methods 0.000 description 58
• 238000002474 experimental method Methods 0.000 description 51
• 108091006146 Channels Proteins 0.000 description 46
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 42
• 230000001413 cellular effect Effects 0.000 description 38
• 241000700159 Rattus Species 0.000 description 37
• 239000011575 calcium Substances 0.000 description 36
• 102000004196 processed proteins & peptides Human genes 0.000 description 33
• 230000014509 gene expression Effects 0.000 description 32
• 239000000975 dye Substances 0.000 description 31
• 239000000243 solution Substances 0.000 description 31
• 241001465754 Metazoa Species 0.000 description 29
• 230000007246 mechanism Effects 0.000 description 28
• 229940024606 amino acid Drugs 0.000 description 27
• 230000006870 function Effects 0.000 description 27
• 238000012360 testing method Methods 0.000 description 27
• 239000002253 acid Substances 0.000 description 26
• 230000004913 activation Effects 0.000 description 26
• 235000001014 amino acid Nutrition 0.000 description 26
• 230000007423 decrease Effects 0.000 description 24
• 230000033228 biological regulation Effects 0.000 description 22
• HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 21
• 229910052791 calcium Inorganic materials 0.000 description 21
• 230000000638 stimulation Effects 0.000 description 21
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 20
• 241000699670 Mus sp. Species 0.000 description 20
• 229960005069 calcium Drugs 0.000 description 20
• 210000004413 cardiac myocyte Anatomy 0.000 description 20
• 238000000338 in vitro Methods 0.000 description 20
• 108090000623 proteins and genes Proteins 0.000 description 20
• 210000000963 osteoblast Anatomy 0.000 description 19
• 230000010412 perfusion Effects 0.000 description 19
• 102100037260 Gap junction beta-1 protein Human genes 0.000 description 18
• 229940079593 drug Drugs 0.000 description 18
• 239000002953 phosphate buffered saline Substances 0.000 description 18
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 17
• 210000004369 blood Anatomy 0.000 description 17
• 239000008280 blood Substances 0.000 description 17
• 238000001727 in vivo Methods 0.000 description 17
• 239000002609 medium Substances 0.000 description 17
• 150000003254 radicals Chemical class 0.000 description 17
• 102000005962 receptors Human genes 0.000 description 17
• 108020003175 receptors Proteins 0.000 description 17
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 16
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 16
• 230000004044 response Effects 0.000 description 16
• 230000007306 turnover Effects 0.000 description 16
• 210000001367 artery Anatomy 0.000 description 15
• 229910052799 carbon Inorganic materials 0.000 description 15
• 229960002748 norepinephrine Drugs 0.000 description 15
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 15
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
• 102000004169 proteins and genes Human genes 0.000 description 15
• 230000001105 regulatory effect Effects 0.000 description 15
• 206010021143 Hypoxia Diseases 0.000 description 14
• 239000006185 dispersion Substances 0.000 description 14
• 230000003834 intracellular effect Effects 0.000 description 14
• 230000001582 osteoblastic effect Effects 0.000 description 14
• 230000026731 phosphorylation Effects 0.000 description 14
• 238000006366 phosphorylation reaction Methods 0.000 description 14
• 235000018102 proteins Nutrition 0.000 description 14
• 238000012546 transfer Methods 0.000 description 14
• 101710177922 Gap junction alpha-5 protein Proteins 0.000 description 13
• 230000027455 binding Effects 0.000 description 13
• 238000009739 binding Methods 0.000 description 13
• 239000003112 inhibitor Substances 0.000 description 13
• 230000019491 signal transduction Effects 0.000 description 13
• 230000035882 stress Effects 0.000 description 13
• 102100030540 Gap junction alpha-5 protein Human genes 0.000 description 12
• 101710202596 Gap junction beta-1 protein Proteins 0.000 description 12
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 12
• 238000001802 infusion Methods 0.000 description 12
• 230000005764 inhibitory process Effects 0.000 description 12
• 210000000274 microglia Anatomy 0.000 description 12
• 210000002569 neuron Anatomy 0.000 description 12
• 230000011664 signaling Effects 0.000 description 12
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 12
• 241000282472 Canis lupus familiaris Species 0.000 description 11
• 206010011086 Coronary artery occlusion Diseases 0.000 description 11
• YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 11
• 102100039290 Gap junction gamma-1 protein Human genes 0.000 description 11
• 101710178004 Gap junction gamma-1 protein Proteins 0.000 description 11
• 230000004075 alteration Effects 0.000 description 11
• 238000004458 analytical method Methods 0.000 description 11
• 210000000170 cell membrane Anatomy 0.000 description 11
• 238000009826 distribution Methods 0.000 description 11
• 210000004379 membrane Anatomy 0.000 description 11
• 239000012528 membrane Substances 0.000 description 11
• 230000008569 process Effects 0.000 description 11
• 239000000523 sample Substances 0.000 description 11
• 230000029663 wound healing Effects 0.000 description 11
• 241000219739 Lens Species 0.000 description 10
• 241000283973 Oryctolagus cuniculus Species 0.000 description 10
• 230000036982 action potential Effects 0.000 description 10
• 210000000709 aorta Anatomy 0.000 description 10
• 238000004113 cell culture Methods 0.000 description 10
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
• 229910052779 Neodymium Inorganic materials 0.000 description 9
• 231100000504 carcinogenesis Toxicity 0.000 description 9
• 230000001684 chronic effect Effects 0.000 description 9
• 239000012530 fluid Substances 0.000 description 9
• 239000001963 growth medium Substances 0.000 description 9
• 239000003446 ligand Substances 0.000 description 9
• 210000004072 lung Anatomy 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• 230000009471 action Effects 0.000 description 8
• 229910002091 carbon monoxide Inorganic materials 0.000 description 8
• 230000000747 cardiac effect Effects 0.000 description 8
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 8
• 150000001923 cyclic compounds Chemical class 0.000 description 8
• 230000001086 cytosolic effect Effects 0.000 description 8
• 230000003828 downregulation Effects 0.000 description 8
• 230000007954 hypoxia Effects 0.000 description 8
• 229960000367 inositol Drugs 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 230000002503 metabolic effect Effects 0.000 description 8
• 238000000520 microinjection Methods 0.000 description 8
• 230000011164 ossification Effects 0.000 description 8
• 230000035699 permeability Effects 0.000 description 8
• 230000008439 repair process Effects 0.000 description 8
• 239000003981 vehicle Substances 0.000 description 8
• ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 7
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 7
• 208000005623 Carcinogenesis Diseases 0.000 description 7
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
• 102000001253 Protein Kinase Human genes 0.000 description 7
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
• 230000001154 acute effect Effects 0.000 description 7
• 229960001456 adenosine triphosphate Drugs 0.000 description 7
• 230000036952 cancer formation Effects 0.000 description 7
• 230000015556 catabolic process Effects 0.000 description 7
• 230000008859 change Effects 0.000 description 7
• 230000008602 contraction Effects 0.000 description 7
• 230000002950 deficient Effects 0.000 description 7
• 230000003511 endothelial effect Effects 0.000 description 7
• 239000011521 glass Substances 0.000 description 7
• 238000003384 imaging method Methods 0.000 description 7
• 210000004495 interstitial cells of cajal Anatomy 0.000 description 7
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
• 229910052757 nitrogen Inorganic materials 0.000 description 7
• 210000000287 oocyte Anatomy 0.000 description 7
• 230000000144 pharmacologic effect Effects 0.000 description 7
• 108060006633 protein kinase Proteins 0.000 description 7
• 230000009467 reduction Effects 0.000 description 7
• 230000002336 repolarization Effects 0.000 description 7
• 239000002356 single layer Substances 0.000 description 7
• 210000002460 smooth muscle Anatomy 0.000 description 7
• 239000000717 tumor promoter Substances 0.000 description 7
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 6
• 102100037156 Gap junction beta-2 protein Human genes 0.000 description 6
• 101710198067 Gap junction beta-2 protein Proteins 0.000 description 6
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
• 229960004373 acetylcholine Drugs 0.000 description 6
• 125000003342 alkenyl group Chemical group 0.000 description 6
• 230000003288 anthiarrhythmic effect Effects 0.000 description 6
• 210000001130 astrocyte Anatomy 0.000 description 6
• 239000012298 atmosphere Substances 0.000 description 6
• 210000002449 bone cell Anatomy 0.000 description 6
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 210000001612 chondrocyte Anatomy 0.000 description 6
• 108010015416 connexin 32 Proteins 0.000 description 6
• 238000006731 degradation reaction Methods 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 210000002919 epithelial cell Anatomy 0.000 description 6
• 239000000835 fiber Substances 0.000 description 6
• 229960002591 hydroxyproline Drugs 0.000 description 6
• 238000011534 incubation Methods 0.000 description 6
• 230000001939 inductive effect Effects 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 238000002372 labelling Methods 0.000 description 6
• 239000010410 layer Substances 0.000 description 6
• 239000011777 magnesium Substances 0.000 description 6
• 238000004519 manufacturing process Methods 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 6
• 230000002269 spontaneous effect Effects 0.000 description 6
• 230000032258 transport Effects 0.000 description 6
• 102000029816 Collagenase Human genes 0.000 description 5
• 108060005980 Collagenase Proteins 0.000 description 5
• 102000001189 Cyclic Peptides Human genes 0.000 description 5
• 108010069514 Cyclic Peptides Proteins 0.000 description 5
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 5
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 5
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 108700020796 Oncogene Proteins 0.000 description 5
• 108010029485 Protein Isoforms Proteins 0.000 description 5
• 102000001708 Protein Isoforms Human genes 0.000 description 5
• 102000003923 Protein Kinase C Human genes 0.000 description 5
• 108090000315 Protein Kinase C Proteins 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 230000002159 abnormal effect Effects 0.000 description 5
• 235000011054 acetic acid Nutrition 0.000 description 5
• 229960000583 acetic acid Drugs 0.000 description 5
• 230000017531 blood circulation Effects 0.000 description 5
• 210000001185 bone marrow Anatomy 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 229960002424 collagenase Drugs 0.000 description 5
• 210000000805 cytoplasm Anatomy 0.000 description 5
• 238000009792 diffusion process Methods 0.000 description 5
• 210000002889 endothelial cell Anatomy 0.000 description 5
• 230000005284 excitation Effects 0.000 description 5
• 210000001156 gastric mucosa Anatomy 0.000 description 5
• 210000002503 granulosa cell Anatomy 0.000 description 5
• 125000001072 heteroaryl group Chemical group 0.000 description 5
• 230000013632 homeostatic process Effects 0.000 description 5
• 238000007912 intraperitoneal administration Methods 0.000 description 5
• 238000013507 mapping Methods 0.000 description 5
• 230000004060 metabolic process Effects 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 235000015097 nutrients Nutrition 0.000 description 5
• 230000001575 pathological effect Effects 0.000 description 5
• 230000037361 pathway Effects 0.000 description 5
• 208000005069 pulmonary fibrosis Diseases 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 229960005322 streptomycin Drugs 0.000 description 5
• 230000001360 synchronised effect Effects 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 4
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
• PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 4
• KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 4
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
• 206010002091 Anaesthesia Diseases 0.000 description 4
• 206010003658 Atrial Fibrillation Diseases 0.000 description 4
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
• 208000013016 Hypoglycemia Diseases 0.000 description 4
• 206010061216 Infarction Diseases 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• 206010030113 Oedema Diseases 0.000 description 4
• 102000043276 Oncogene Human genes 0.000 description 4
• 206010033647 Pancreatitis acute Diseases 0.000 description 4
• 229930182555 Penicillin Natural products 0.000 description 4
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
• ONPXCLZMBSJLSP-CSMHCCOUSA-N Pro-Hyp Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)[C@H]1NCCC1 ONPXCLZMBSJLSP-CSMHCCOUSA-N 0.000 description 4
• RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 4
• 229910052770 Uranium Inorganic materials 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 201000003229 acute pancreatitis Diseases 0.000 description 4
• 230000037005 anaesthesia Effects 0.000 description 4
• 210000003050 axon Anatomy 0.000 description 4
• 230000004888 barrier function Effects 0.000 description 4
• 238000003287 bathing Methods 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 230000005540 biological transmission Effects 0.000 description 4
• 238000010322 bone marrow transplantation Methods 0.000 description 4
• 235000011148 calcium chloride Nutrition 0.000 description 4
• 229910001424 calcium ion Inorganic materials 0.000 description 4
• 125000004432 carbon atom Chemical group C* 0.000 description 4
• 230000008568 cell cell communication Effects 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 230000006735 deficit Effects 0.000 description 4
• 210000003038 endothelium Anatomy 0.000 description 4
• 239000002158 endotoxin Substances 0.000 description 4
• 238000011067 equilibration Methods 0.000 description 4
• 210000002950 fibroblast Anatomy 0.000 description 4
• YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 4
• 201000005917 gastric ulcer Diseases 0.000 description 4
• 239000003102 growth factor Substances 0.000 description 4
• 210000002837 heart atrium Anatomy 0.000 description 4
• 229960002897 heparin Drugs 0.000 description 4
• 229920000669 heparin Polymers 0.000 description 4
• 230000002218 hypoglycaemic effect Effects 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• 238000011065 in-situ storage Methods 0.000 description 4
• 230000007574 infarction Effects 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 230000007775 late Effects 0.000 description 4
• 210000005240 left ventricle Anatomy 0.000 description 4
• 229920006008 lipopolysaccharide Polymers 0.000 description 4
• 230000033001 locomotion Effects 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 239000003607 modifier Substances 0.000 description 4
• 210000004165 myocardium Anatomy 0.000 description 4
• 125000004433 nitrogen atom Chemical group N* 0.000 description 4
• 235000016709 nutrition Nutrition 0.000 description 4
• 229940049954 penicillin Drugs 0.000 description 4
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
• 239000012071 phase Substances 0.000 description 4
• 230000003169 placental effect Effects 0.000 description 4
• 239000011148 porous material Substances 0.000 description 4
• 238000002203 pretreatment Methods 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 108010077112 prolyl-proline Proteins 0.000 description 4
• 230000000644 propagated effect Effects 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 239000000700 radioactive tracer Substances 0.000 description 4
• 238000011084 recovery Methods 0.000 description 4
• 210000003491 skin Anatomy 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
• 210000000130 stem cell Anatomy 0.000 description 4
• 230000008093 supporting effect Effects 0.000 description 4
• 230000002459 sustained effect Effects 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• 210000002700 urine Anatomy 0.000 description 4
• 230000000283 vasomotion Effects 0.000 description 4
• 230000006498 vasomotor response Effects 0.000 description 4
• UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 3
• OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
• 206010002660 Anoxia Diseases 0.000 description 3
• 241000976983 Anoxia Species 0.000 description 3
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
• 206010003671 Atrioventricular Block Diseases 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• 241000700198 Cavia Species 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
• 101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 description 3
• 206010021639 Incontinence Diseases 0.000 description 3
• 108090001061 Insulin Proteins 0.000 description 3
• 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 3
• 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 3
• 108090000862 Ion Channels Proteins 0.000 description 3
• 102000004310 Ion Channels Human genes 0.000 description 3
• 102100037644 Kelch-like protein 41 Human genes 0.000 description 3
• 108050003242 Kelch-like protein 41 Proteins 0.000 description 3
• 239000012839 Krebs-Henseleit buffer Substances 0.000 description 3
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 3
• 108091054455 MAP kinase family Proteins 0.000 description 3
• 102000043136 MAP kinase family Human genes 0.000 description 3
• 206010061309 Neoplasm progression Diseases 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 108010043958 Peptoids Proteins 0.000 description 3
• 102100036829 Probable peptidyl-tRNA hydrolase Human genes 0.000 description 3
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 208000007536 Thrombosis Diseases 0.000 description 3
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
• 238000001949 anaesthesia Methods 0.000 description 3
• 230000007953 anoxia Effects 0.000 description 3
• 239000003416 antiarrhythmic agent Substances 0.000 description 3
• 208000002399 aphthous stomatitis Diseases 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 125000004429 atom Chemical group 0.000 description 3
• 230000002238 attenuated effect Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 3
• 230000008827 biological function Effects 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 102100022422 cGMP-dependent protein kinase 1 Human genes 0.000 description 3
• 125000002843 carboxylic acid group Chemical group 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 210000000038 chest Anatomy 0.000 description 3
• 239000000470 constituent Substances 0.000 description 3
• 231100000895 deafness Toxicity 0.000 description 3
• 230000003205 diastolic effect Effects 0.000 description 3
• 235000005911 diet Nutrition 0.000 description 3
• 230000037213 diet Effects 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 235000021186 dishes Nutrition 0.000 description 3
• 210000004242 electrical synapse Anatomy 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 239000000706 filtrate Substances 0.000 description 3
• 229940028334 follicle stimulating hormone Drugs 0.000 description 3
• 230000007946 glucose deprivation Effects 0.000 description 3
• 210000002768 hair cell Anatomy 0.000 description 3
• 238000003306 harvesting Methods 0.000 description 3
• 230000023597 hemostasis Effects 0.000 description 3
• 125000005842 heteroatom Chemical group 0.000 description 3
• 230000000396 hypokalemic effect Effects 0.000 description 3
• 230000001146 hypoxic effect Effects 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 210000000936 intestine Anatomy 0.000 description 3
• 230000036724 intravesical pressure Effects 0.000 description 3
• 210000004153 islets of langerhan Anatomy 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 229910052749 magnesium Inorganic materials 0.000 description 3
• 230000035800 maturation Effects 0.000 description 3
• 238000000386 microscopy Methods 0.000 description 3
• DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 3
• 229960003793 midazolam Drugs 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 230000004118 muscle contraction Effects 0.000 description 3
• 230000002107 myocardial effect Effects 0.000 description 3
• 208000010125 myocardial infarction Diseases 0.000 description 3
• 210000000754 myometrium Anatomy 0.000 description 3
• 210000000653 nervous system Anatomy 0.000 description 3
• 210000004498 neuroglial cell Anatomy 0.000 description 3
• NPKKRSHVJIQBKU-UHFFFAOYSA-N ornogenin Natural products CC(OC(=O)C=Cc1ccccc1)C2(O)CCC3(O)C4(O)CC=C5CC(O)CCC5(C)C4CC(OC(=O)C=Cc6ccccc6)C23C NPKKRSHVJIQBKU-UHFFFAOYSA-N 0.000 description 3
• 230000002611 ovarian Effects 0.000 description 3
• 230000016087 ovulation Effects 0.000 description 3
• DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 3
• 229960002695 phenobarbital Drugs 0.000 description 3
• 235000021317 phosphate Nutrition 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 235000021251 pulses Nutrition 0.000 description 3
• 230000036279 refractory period Effects 0.000 description 3
• 230000004043 responsiveness Effects 0.000 description 3
• 238000005070 sampling Methods 0.000 description 3
• 230000009870 specific binding Effects 0.000 description 3
• 208000003265 stomatitis Diseases 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 210000001550 testis Anatomy 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 230000005751 tumor progression Effects 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 235000002374 tyrosine Nutrition 0.000 description 3
• 229960004441 tyrosine Drugs 0.000 description 3
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 210000004291 uterus Anatomy 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 description 2
• WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
• YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
• KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
• PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
• MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 2
• 239000004382 Amylase Substances 0.000 description 2
• 108010065511 Amylases Proteins 0.000 description 2
• 102000013142 Amylases Human genes 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• 208000006386 Bone Resorption Diseases 0.000 description 2
• 208000020084 Bone disease Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 2
• 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 2
• 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• 108010010737 Ceruletide Proteins 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• 150000008574 D-amino acids Chemical group 0.000 description 2
• HXEACLLIILLPRG-RXMQYKEDSA-N D-pipecolic acid Chemical compound OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 2
• 206010011903 Deafness traumatic Diseases 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 206010012305 Demyelination Diseases 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• XFYIHRTWDXNCTA-UHFFFAOYSA-N Eugenin Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC1CCC2C(C)(CCC3C2(C)CCC4(C)C5CC(C)(C)CCC5(C)CCC34C)C1C XFYIHRTWDXNCTA-UHFFFAOYSA-N 0.000 description 2
• 206010063560 Excessive granulation tissue Diseases 0.000 description 2
• 108700024394 Exon Proteins 0.000 description 2
• 102000009123 Fibrin Human genes 0.000 description 2
• 108010073385 Fibrin Proteins 0.000 description 2
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
• 108010067306 Fibronectins Proteins 0.000 description 2
• 102000016359 Fibronectins Human genes 0.000 description 2
• 102100030526 Gap junction alpha-3 protein Human genes 0.000 description 2
• 101710198379 Gap junction alpha-3 protein Proteins 0.000 description 2
• 102100030525 Gap junction alpha-4 protein Human genes 0.000 description 2
• 101710190724 Gap junction alpha-4 protein Proteins 0.000 description 2
• 102100025283 Gap junction alpha-8 protein Human genes 0.000 description 2
• 101710086969 Gap junction alpha-8 protein Proteins 0.000 description 2
• 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
• 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 206010019695 Hepatic neoplasm Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000727821 Homo sapiens RING1 and YY1-binding protein Proteins 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 206010023232 Joint swelling Diseases 0.000 description 2
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
• 150000008575 L-amino acids Chemical group 0.000 description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
• YPIQVCUJEKAZCP-UHFFFAOYSA-N Malotilate Chemical compound CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 YPIQVCUJEKAZCP-UHFFFAOYSA-N 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
• OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
• 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 2
• 108090000573 Osteocalcin Proteins 0.000 description 2
• 102000004067 Osteocalcin Human genes 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 206010036626 Presbyacusis Diseases 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• 102000000033 Purinergic Receptors Human genes 0.000 description 2
• 108010080192 Purinergic Receptors Proteins 0.000 description 2
• 102100029760 RING1 and YY1-binding protein Human genes 0.000 description 2
• 241000700157 Rattus norvegicus Species 0.000 description 2
• 206010041899 Stab wound Diseases 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 241000223109 Trypanosoma cruzi Species 0.000 description 2
• VNYDHJARLHNEGA-RYUDHWBXSA-N Tyr-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 description 2
• 210000003489 abdominal muscle Anatomy 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 230000010933 acylation Effects 0.000 description 2
• 238000005917 acylation reaction Methods 0.000 description 2
• UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 150000001335 aliphatic alkanes Chemical class 0.000 description 2
• 150000001447 alkali salts Chemical class 0.000 description 2
• 235000019418 amylase Nutrition 0.000 description 2
• 230000003444 anaesthetic effect Effects 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 230000002763 arrhythmic effect Effects 0.000 description 2
• 210000002565 arteriole Anatomy 0.000 description 2
• 125000004104 aryloxy group Chemical group 0.000 description 2
• 230000003305 autocrine Effects 0.000 description 2
• 150000001540 azides Chemical class 0.000 description 2
• 235000013405 beer Nutrition 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 230000036770 blood supply Effects 0.000 description 2
• 230000024279 bone resorption Effects 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 230000005587 bubbling Effects 0.000 description 2
• 239000007853 buffer solution Substances 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 230000003317 calciotropic effect Effects 0.000 description 2
• 244000309466 calf Species 0.000 description 2
• UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 2
• 231100000357 carcinogen Toxicity 0.000 description 2
• 239000003183 carcinogenic agent Substances 0.000 description 2
• 210000005242 cardiac chamber Anatomy 0.000 description 2
• 239000000679 carrageenan Substances 0.000 description 2
• 229920001525 carrageenan Polymers 0.000 description 2
• 229940113118 carrageenan Drugs 0.000 description 2
• 150000003943 catecholamines Chemical class 0.000 description 2
• 230000022131 cell cycle Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000012292 cell migration Effects 0.000 description 2
• 230000009134 cell regulation Effects 0.000 description 2
• 230000023549 cell-cell signaling Effects 0.000 description 2
• 230000010267 cellular communication Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• YRALAIOMGQZKOW-HYAOXDFASA-N ceruletide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-HYAOXDFASA-N 0.000 description 2
• 230000002113 chemopreventative effect Effects 0.000 description 2
• 230000015271 coagulation Effects 0.000 description 2
• 238000005345 coagulation Methods 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 229940126086 compound 21 Drugs 0.000 description 2
• 229940126208 compound 22 Drugs 0.000 description 2
• 229940125844 compound 46 Drugs 0.000 description 2
• 108010015404 connexin 38 Proteins 0.000 description 2
• 210000005226 corpus cavernosum Anatomy 0.000 description 2
• 210000004246 corpus luteum Anatomy 0.000 description 2
• 238000012937 correction Methods 0.000 description 2
• 230000001054 cortical effect Effects 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 238000000586 desensitisation Methods 0.000 description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
• 229960003957 dexamethasone Drugs 0.000 description 2
• 238000006073 displacement reaction Methods 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 238000001647 drug administration Methods 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 210000003027 ear inner Anatomy 0.000 description 2
• 238000002001 electrophysiology Methods 0.000 description 2
• 230000007831 electrophysiology Effects 0.000 description 2
• 210000002308 embryonic cell Anatomy 0.000 description 2
• 210000002257 embryonic structure Anatomy 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 230000009986 erectile function Effects 0.000 description 2
• SUTUBQHKZRNZRA-UHFFFAOYSA-N eugenin Chemical compound O1C(C)=CC(=O)C=2C1=CC(OC)=CC=2O SUTUBQHKZRNZRA-UHFFFAOYSA-N 0.000 description 2
• 238000013401 experimental design Methods 0.000 description 2
• 210000003754 fetus Anatomy 0.000 description 2
• 229950003499 fibrin Drugs 0.000 description 2
• 210000000968 fibrocartilage Anatomy 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 230000004907 flux Effects 0.000 description 2
• 230000003325 follicular Effects 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 210000004195 gingiva Anatomy 0.000 description 2
• 230000002518 glial effect Effects 0.000 description 2
• 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
• 229960002449 glycine Drugs 0.000 description 2
• 210000001126 granulation tissue Anatomy 0.000 description 2
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
• 229960003132 halothane Drugs 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 210000005003 heart tissue Anatomy 0.000 description 2
• 210000003494 hepatocyte Anatomy 0.000 description 2
• 235000003642 hunger Nutrition 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 230000030214 innervation Effects 0.000 description 2
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 230000008776 intercellular pathway Effects 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 238000011813 knockout mouse model Methods 0.000 description 2
• 210000003644 lens cell Anatomy 0.000 description 2
• 231100000518 lethal Toxicity 0.000 description 2
• 230000001665 lethal effect Effects 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 210000003141 lower extremity Anatomy 0.000 description 2
• DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 229950000470 malotilate Drugs 0.000 description 2
• 230000021121 meiosis Effects 0.000 description 2
• 230000028161 membrane depolarization Effects 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 230000002025 microglial effect Effects 0.000 description 2
• 239000003226 mitogen Substances 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 208000031225 myocardial ischemia Diseases 0.000 description 2
• 210000004457 myocytus nodalis Anatomy 0.000 description 2
• 230000002632 myometrial effect Effects 0.000 description 2
• IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
• 230000001338 necrotic effect Effects 0.000 description 2
• 230000010309 neoplastic transformation Effects 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 230000007959 normoxia Effects 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 230000002246 oncogenic effect Effects 0.000 description 2
• 238000007410 oral glucose tolerance test Methods 0.000 description 2
• 230000008520 organization Effects 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 210000002394 ovarian follicle Anatomy 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 239000000816 peptidomimetic Substances 0.000 description 2
• 208000003013 permanent neonatal diabetes mellitus Diseases 0.000 description 2
• LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
• 238000005222 photoaffinity labeling Methods 0.000 description 2
• 238000006303 photolysis reaction Methods 0.000 description 2
• 230000015843 photosynthesis, light reaction Effects 0.000 description 2
• 230000004962 physiological condition Effects 0.000 description 2
• 230000001817 pituitary effect Effects 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 230000003334 potential effect Effects 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 230000002028 premature Effects 0.000 description 2
• 208000009800 presbycusis Diseases 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 230000030198 regulation of embryonic development Effects 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 230000033764 rhythmic process Effects 0.000 description 2
• 230000001020 rhythmical effect Effects 0.000 description 2
• 210000005241 right ventricle Anatomy 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 229940054269 sodium pyruvate Drugs 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 230000037351 starvation Effects 0.000 description 2
• 210000001562 sternum Anatomy 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 210000002536 stromal cell Anatomy 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• CYFLXLSBHQBMFT-UHFFFAOYSA-N sulfamoxole Chemical group O1C(C)=C(C)N=C1NS(=O)(=O)C1=CC=C(N)C=C1 CYFLXLSBHQBMFT-UHFFFAOYSA-N 0.000 description 2
• YRALAIOMGQZKOW-UHFFFAOYSA-N sulfated caerulein Natural products C=1C=CC=CC=1CC(C(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C1NC(=O)CC1)CC1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-UHFFFAOYSA-N 0.000 description 2
• 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 230000003319 supportive effect Effects 0.000 description 2
• 210000000225 synapse Anatomy 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 230000003390 teratogenic effect Effects 0.000 description 2
• 210000000115 thoracic cavity Anatomy 0.000 description 2
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 230000001960 triggered effect Effects 0.000 description 2
• 108010020532 tyrosyl-proline Proteins 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 230000004865 vascular response Effects 0.000 description 2
• 230000024883 vasodilation Effects 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 201000002282 venous insufficiency Diseases 0.000 description 2
• 102000009310 vitamin D receptors Human genes 0.000 description 2
• 108050000156 vitamin D receptors Proteins 0.000 description 2
• ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
• SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
• BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
• GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
• WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical group OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
• QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
• UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
• RSDQBPGKMDFRHH-MJVIGCOGSA-N (3s,3as,5ar,9bs)-3,5a,9-trimethyl-3a,4,5,7,8,9b-hexahydro-3h-benzo[g][1]benzofuran-2,6-dione Chemical compound O=C([C@]1(C)CC2)CCC(C)=C1[C@@H]1[C@@H]2[C@H](C)C(=O)O1 RSDQBPGKMDFRHH-MJVIGCOGSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
• NWJZWHGSBTVTGM-UHFFFAOYSA-N 1-[bis(aziridin-1-yl)phosphoryl]-3-phenylurea Chemical compound C1CN1P(=O)(N1CC1)NC(=O)NC1=CC=CC=C1 NWJZWHGSBTVTGM-UHFFFAOYSA-N 0.000 description 1
• WSNDAYQNZRJGMJ-UHFFFAOYSA-N 2,2,2-trifluoroethanone Chemical compound FC(F)(F)[C]=O WSNDAYQNZRJGMJ-UHFFFAOYSA-N 0.000 description 1
• BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
• LPXHPAYRONCQIF-UHFFFAOYSA-N 2-(2-hydroxyphenoxy)acetic acid Chemical compound OC(=O)COC1=CC=CC=C1O LPXHPAYRONCQIF-UHFFFAOYSA-N 0.000 description 1
• OQMYZVWIXPPDDE-UHFFFAOYSA-N 2-(cyclohexylazaniumyl)acetate Chemical compound OC(=O)CNC1CCCCC1 OQMYZVWIXPPDDE-UHFFFAOYSA-N 0.000 description 1
• VUCNQOPCYRJCGQ-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenoxy]acetic acid Chemical compound OCC1=CC=C(OCC(O)=O)C=C1 VUCNQOPCYRJCGQ-UHFFFAOYSA-N 0.000 description 1
• WYFYSTBFFDOVJW-UHFFFAOYSA-L 2-[4-[4-(3,5-diphenyltetrazol-2-ium-2-yl)phenyl]phenyl]-3,5-diphenyltetrazol-2-ium;dichloride Chemical compound [Cl-].[Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC(=CC=2)C=2C=CC(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=NN1C1=CC=CC=C1 WYFYSTBFFDOVJW-UHFFFAOYSA-L 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
• PKGWLCZTTHWKIZ-UHFFFAOYSA-N 4-Hydroxypheoxyacetate Chemical compound OC(=O)COC1=CC=C(O)C=C1 PKGWLCZTTHWKIZ-UHFFFAOYSA-N 0.000 description 1
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
• 241001514645 Agonis Species 0.000 description 1
• HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 1
• 206010001935 American trypanosomiasis Diseases 0.000 description 1
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 206010003402 Arthropod sting Diseases 0.000 description 1
• 208000033116 Asbestos intoxication Diseases 0.000 description 1
• FYRVDDJMNISIKJ-UWVGGRQHSA-N Asn-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FYRVDDJMNISIKJ-UWVGGRQHSA-N 0.000 description 1
• 101100354312 Bacillus subtilis (strain 168) licC gene Proteins 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 206010004668 Biliary neoplasm Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• 102400000967 Bradykinin Human genes 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 206010006578 Bundle-Branch Block Diseases 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 206010007759 Cataract nuclear Diseases 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 208000024699 Chagas disease Diseases 0.000 description 1
• OJYGBLRPYBAHRT-OPKHMCHVSA-N Chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H](C(O)CO)OC21 OJYGBLRPYBAHRT-OPKHMCHVSA-N 0.000 description 1
• VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 229940126639 Compound 33 Drugs 0.000 description 1
• 229940127007 Compound 39 Drugs 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 208000027205 Congenital disease Diseases 0.000 description 1
• 206010010539 Congenital megacolon Diseases 0.000 description 1
• 206010062346 Congenital neuropathy Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 102000014824 Crystallins Human genes 0.000 description 1
• 108010064003 Crystallins Proteins 0.000 description 1
• 208000014311 Cushing syndrome Diseases 0.000 description 1
• 206010011732 Cyst Diseases 0.000 description 1
• 102000005927 Cysteine Proteases Human genes 0.000 description 1
• 108010005843 Cysteine Proteases Proteins 0.000 description 1
• CXISPYVYMQWFLE-GSVOUGTGSA-N D-Ala-Gly Chemical compound C[C@@H](N)C(=O)NCC(O)=O CXISPYVYMQWFLE-GSVOUGTGSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 241000283014 Dama Species 0.000 description 1
• 208000033986 Device capturing issue Diseases 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 208000006402 Ductal Carcinoma Diseases 0.000 description 1
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 241001547070 Eriodes Species 0.000 description 1
• 101100410352 Escherichia coli (strain K12) chbC gene Proteins 0.000 description 1
• 101100129092 Escherichia coli hic gene Proteins 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 208000009386 Experimental Arthritis Diseases 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
• 206010016803 Fluid overload Diseases 0.000 description 1
• 229940123457 Free radical scavenger Drugs 0.000 description 1
• 102100039397 Gap junction beta-3 protein Human genes 0.000 description 1
• 101710082451 Gap junction beta-3 protein Proteins 0.000 description 1
• 102100039401 Gap junction beta-6 protein Human genes 0.000 description 1
• 101710188943 Gap junction beta-6 protein Proteins 0.000 description 1
• 102100025623 Gap junction delta-2 protein Human genes 0.000 description 1
• 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
• 239000004366 Glucose oxidase Substances 0.000 description 1
• 108010015776 Glucose oxidase Proteins 0.000 description 1
• QIZJOTQTCAGKPU-KWQFWETISA-N Gly-Ala-Tyr Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 QIZJOTQTCAGKPU-KWQFWETISA-N 0.000 description 1
• JVACNFOPSUPDTK-QWRGUYRKSA-N Gly-Asn-Phe Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JVACNFOPSUPDTK-QWRGUYRKSA-N 0.000 description 1
• LURCIJSJAKFCRO-QWRGUYRKSA-N Gly-Asn-Tyr Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LURCIJSJAKFCRO-QWRGUYRKSA-N 0.000 description 1
• INLIXXRWNUKVCF-JTQLQIEISA-N Gly-Gly-Tyr Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 INLIXXRWNUKVCF-JTQLQIEISA-N 0.000 description 1
• VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• 208000004592 Hirschsprung disease Diseases 0.000 description 1
• 101000616432 Homo sapiens Microtubule-associated protein 6 Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 206010020853 Hypertonic bladder Diseases 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• 241000756171 Hypoxis Species 0.000 description 1
• 210000002370 ICC Anatomy 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 238000012404 In vitro experiment Methods 0.000 description 1
• 208000020060 Increased inflammatory response Diseases 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 206010022562 Intermittent claudication Diseases 0.000 description 1
• PJLVTVAIERNDEQ-BTJKTKAUSA-N Irsogladine maleate Chemical compound OC(=O)\C=C/C(O)=O.NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 PJLVTVAIERNDEQ-BTJKTKAUSA-N 0.000 description 1
• 208000035901 Ischaemic ulcer Diseases 0.000 description 1
• 241000820057 Ithone Species 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
• 241000283953 Lagomorpha Species 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 208000002720 Malnutrition Diseases 0.000 description 1
• 241001436793 Meru Species 0.000 description 1
• 208000029725 Metabolic bone disease Diseases 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 102100021791 Microtubule-associated protein 6 Human genes 0.000 description 1
• 241001024304 Mino Species 0.000 description 1
• 101710166076 Mitogen-activated protein kinase 5 Proteins 0.000 description 1
• 108700005084 Multigene Family Proteins 0.000 description 1
• 101100445397 Mus musculus Ephb6 gene Proteins 0.000 description 1
• WRUZLCLJULHLEY-UHFFFAOYSA-N N-(p-hydroxyphenyl)glycine Chemical compound OC(=O)CNC1=CC=C(O)C=C1 WRUZLCLJULHLEY-UHFFFAOYSA-N 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• 108010079364 N-glycylalanine Proteins 0.000 description 1
• NPKSPKHJBVJUKB-UHFFFAOYSA-N N-phenylglycine Chemical compound OC(=O)CNC1=CC=CC=C1 NPKSPKHJBVJUKB-UHFFFAOYSA-N 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000032976 Neuroendocrine carcinoma of pancreas Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 101100281518 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fox-2 gene Proteins 0.000 description 1
• 206010052400 Oedematous pancreatitis Diseases 0.000 description 1
• 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
• 102400000050 Oxytocin Human genes 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010033661 Pancytopenia Diseases 0.000 description 1
• 240000002390 Pandanus odoratissimus Species 0.000 description 1
• 235000005311 Pandanus odoratissimus Nutrition 0.000 description 1
• 241000282320 Panthera leo Species 0.000 description 1
• 208000010886 Peripheral nerve injury Diseases 0.000 description 1
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 235000014676 Phragmites communis Nutrition 0.000 description 1
• 241000920340 Pion Species 0.000 description 1
• 206010035742 Pneumonitis Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 241000079451 Prasma Species 0.000 description 1
• 102100025803 Progesterone receptor Human genes 0.000 description 1
• 229940096437 Protein S Drugs 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 208000036366 Sensation of pressure Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 244000191761 Sida cordifolia Species 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 201000010001 Silicosis Diseases 0.000 description 1
• PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
• 208000007718 Stable Angina Diseases 0.000 description 1
• 229910000831 Steel Inorganic materials 0.000 description 1
• 241001611093 Stimula Species 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
• 206010042434 Sudden death Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 108700025695 Suppressor Genes Proteins 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• RSDQBPGKMDFRHH-UHFFFAOYSA-N Taurin Natural products C1CC2(C)C(=O)CCC(C)=C2C2C1C(C)C(=O)O2 RSDQBPGKMDFRHH-UHFFFAOYSA-N 0.000 description 1
• IOYNQIMAUDJVEI-BMVIKAAMSA-N Tepraloxydim Chemical group C1C(=O)C(C(=N/OC\C=C\Cl)/CC)=C(O)CC1C1CCOCC1 IOYNQIMAUDJVEI-BMVIKAAMSA-N 0.000 description 1
• 241000906446 Theraps Species 0.000 description 1
• 241000534944 Thia Species 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 206010070863 Toxicity to various agents Diseases 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 241000223104 Trypanosoma Species 0.000 description 1
• 102000014384 Type C Phospholipases Human genes 0.000 description 1
• 108010079194 Type C Phospholipases Proteins 0.000 description 1
• NLKUJNGEGZDXGO-XVKPBYJWSA-N Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NLKUJNGEGZDXGO-XVKPBYJWSA-N 0.000 description 1
• 208000007814 Unstable Angina Diseases 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 241001433070 Xiphoides Species 0.000 description 1
• MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
• PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
• PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
• SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
• 239000003929 acidic solution Substances 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 206010000891 acute myocardial infarction Diseases 0.000 description 1
• 230000002730 additional effect Effects 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 230000004520 agglutination Effects 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 208000037883 airway inflammation Diseases 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
• 229940093740 amino acid and derivative Drugs 0.000 description 1
• 150000003862 amino acid derivatives Chemical class 0.000 description 1
• QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
• 229960003375 aminomethylbenzoic acid Drugs 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 229960003942 amphotericin b Drugs 0.000 description 1
• 229940124326 anaesthetic agent Drugs 0.000 description 1
• 210000003484 anatomy Anatomy 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 230000001656 angiogenetic effect Effects 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000003178 anti-diabetic effect Effects 0.000 description 1
• 229940124350 antibacterial drug Drugs 0.000 description 1
• 239000003472 antidiabetic agent Substances 0.000 description 1
• 239000003699 antiulcer agent Substances 0.000 description 1
• 210000002403 aortic endothelial cell Anatomy 0.000 description 1
• 206010002906 aortic stenosis Diseases 0.000 description 1
• 210000001765 aortic valve Anatomy 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 125000003435 aroyl group Chemical group 0.000 description 1
• 230000004872 arterial blood pressure Effects 0.000 description 1
• 206010063452 arteriosclerotic retinopathy Diseases 0.000 description 1
• 230000027746 artery morphogenesis Effects 0.000 description 1
• 210000001188 articular cartilage Anatomy 0.000 description 1
• 206010003441 asbestosis Diseases 0.000 description 1
• 230000001174 ascending effect Effects 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 230000000712 assembly Effects 0.000 description 1
• 238000000429 assembly Methods 0.000 description 1
• 230000003140 astrocytic effect Effects 0.000 description 1
• XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
• 210000001008 atrial appendage Anatomy 0.000 description 1
• 210000001992 atrioventricular node Anatomy 0.000 description 1
• 230000002567 autonomic effect Effects 0.000 description 1
• 210000000467 autonomic pathway Anatomy 0.000 description 1
• 230000010455 autoregulation Effects 0.000 description 1
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 239000003855 balanced salt solution Substances 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
• 239000012965 benzophenone Substances 0.000 description 1
• 229940000635 beta-alanine Drugs 0.000 description 1
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000007321 biological mechanism Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000004155 blood-retinal barrier Anatomy 0.000 description 1
• 230000004378 blood-retinal barrier Effects 0.000 description 1
• 239000001045 blue dye Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 210000002805 bone matrix Anatomy 0.000 description 1
• 239000005388 borosilicate glass Substances 0.000 description 1
• 208000006218 bradycardia Diseases 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 210000003123 bronchiole Anatomy 0.000 description 1
• 210000004375 bundle of his Anatomy 0.000 description 1
• 230000002308 calcification Effects 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 229960002713 calcium chloride Drugs 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 125000005587 carbonate group Chemical group 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 230000022159 cartilage development Effects 0.000 description 1
• 230000003532 cataractogenesis Effects 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 101150080131 celB gene Proteins 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 239000013553 cell monolayer Substances 0.000 description 1
• 230000010001 cellular homeostasis Effects 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 230000002057 chronotropic effect Effects 0.000 description 1
• CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
• 229960001380 cimetidine Drugs 0.000 description 1
• 230000002060 circadian Effects 0.000 description 1
• 230000027288 circadian rhythm Effects 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• BJBUEDPLEOHJGE-IUYQGCFVSA-N cis-3-hydroxy-D-proline zwitterion Chemical compound O[C@H]1CCN[C@H]1C(O)=O BJBUEDPLEOHJGE-IUYQGCFVSA-N 0.000 description 1
• 230000007012 clinical effect Effects 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 229940125797 compound 12 Drugs 0.000 description 1
• 229940126543 compound 14 Drugs 0.000 description 1
• 229940125810 compound 20 Drugs 0.000 description 1
• 229940125961 compound 24 Drugs 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 229940125877 compound 31 Drugs 0.000 description 1
• 229940126540 compound 41 Drugs 0.000 description 1
• 229940125936 compound 42 Drugs 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 108010015417 connexin 36 Proteins 0.000 description 1
• 230000008828 contractile function Effects 0.000 description 1
• 238000011254 conventional chemotherapy Methods 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 210000000243 deiters cell Anatomy 0.000 description 1
• 230000030609 dephosphorylation Effects 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000001687 destabilization Effects 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 150000008049 diazo compounds Chemical class 0.000 description 1
• 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
• JNSGIVNNHKGGRU-JYRVWZFOSA-N diethoxyphosphinothioyl (2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetate Chemical compound CCOP(=S)(OCC)OC(=O)C(=N/OC)\C1=CSC(N)=N1 JNSGIVNNHKGGRU-JYRVWZFOSA-N 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
• 208000032625 disorder of ear Diseases 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 230000008846 dynamic interplay Effects 0.000 description 1
• 230000037024 effective refractory period Effects 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 238000003372 electrophysiological method Methods 0.000 description 1
• 210000001174 endocardium Anatomy 0.000 description 1
• 210000003060 endolymph Anatomy 0.000 description 1
• 208000005457 endolymphatic hydrops Diseases 0.000 description 1
• 230000008753 endothelial function Effects 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000007515 enzymatic degradation Effects 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 102000015694 estrogen receptors Human genes 0.000 description 1
• 108010038795 estrogen receptors Proteins 0.000 description 1
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 210000001723 extracellular space Anatomy 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 210000000416 exudates and transudate Anatomy 0.000 description 1
• 210000001105 femoral artery Anatomy 0.000 description 1
• 210000003191 femoral vein Anatomy 0.000 description 1
• 210000002436 femur neck Anatomy 0.000 description 1
• IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
• 229960004207 fentanyl citrate Drugs 0.000 description 1
• 230000035558 fertility Effects 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 description 1
• 229960005220 fluanisone Drugs 0.000 description 1
• 238000000799 fluorescence microscopy Methods 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 235000013373 food additive Nutrition 0.000 description 1
• 239000002778 food additive Substances 0.000 description 1
• 210000002683 foot Anatomy 0.000 description 1
• 210000000245 forearm Anatomy 0.000 description 1
• 210000003194 forelimb Anatomy 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• VPSRLGDRGCKUTK-UHFFFAOYSA-N fura-2-acetoxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=CC2=C1OC(C=1OC(=CN=1)C(=O)OCOC(C)=O)=C2 VPSRLGDRGCKUTK-UHFFFAOYSA-N 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 230000004077 genetic alteration Effects 0.000 description 1
• 231100000118 genetic alteration Toxicity 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229940116332 glucose oxidase Drugs 0.000 description 1
• 235000019420 glucose oxidase Nutrition 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 150000002332 glycine derivatives Chemical class 0.000 description 1
• 229960004275 glycolic acid Drugs 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
• 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 1
• JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
• 210000004524 haematopoietic cell Anatomy 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 230000000004 hemodynamic effect Effects 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 210000000548 hind-foot Anatomy 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 108091008039 hormone receptors Proteins 0.000 description 1
• 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
• 150000002430 hydrocarbons Chemical group 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 150000001261 hydroxy acids Chemical class 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 230000002102 hyperpolarization Effects 0.000 description 1
• 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 1
• 238000005286 illumination Methods 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 210000004713 immature microglia Anatomy 0.000 description 1
• 239000012642 immune effector Substances 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000006749 inflammatory damage Effects 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 239000002917 insecticide Substances 0.000 description 1
• 238000006713 insertion reaction Methods 0.000 description 1
• 230000003914 insulin secretion Effects 0.000 description 1
• 206010022498 insulinoma Diseases 0.000 description 1
• 230000005732 intercellular adhesion Effects 0.000 description 1
• 210000004692 intercellular junction Anatomy 0.000 description 1
• 230000035990 intercellular signaling Effects 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 230000035987 intoxication Effects 0.000 description 1
• 231100000566 intoxication Toxicity 0.000 description 1
• 230000037041 intracellular level Effects 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 210000003093 intracellular space Anatomy 0.000 description 1
• 230000010189 intracellular transport Effects 0.000 description 1
• 238000010988 intraclass correlation coefficient Methods 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229940044173 iodine-125 Drugs 0.000 description 1
• 230000037427 ion transport Effects 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000005567 liquid scintillation counting Methods 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
• 208000004731 long QT syndrome Diseases 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 230000004199 lung function Effects 0.000 description 1
• XDOFWFNMYJRHEW-UHFFFAOYSA-N m-hydroxyhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(O)=C1 XDOFWFNMYJRHEW-UHFFFAOYSA-N 0.000 description 1
• 230000007257 malfunction Effects 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 235000000824 malnutrition Nutrition 0.000 description 1
• 230000001071 malnutrition Effects 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 210000001370 mediastinum Anatomy 0.000 description 1
• 208000004840 megacolon Diseases 0.000 description 1
• 210000002752 melanocyte Anatomy 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 210000003975 mesenteric artery Anatomy 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 239000013586 microbial product Substances 0.000 description 1
• 229940025758 midazolam 5 mg/ml Drugs 0.000 description 1
• 230000001617 migratory effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
• 150000004712 monophosphates Chemical class 0.000 description 1
• 230000001002 morphogenetic effect Effects 0.000 description 1
• 230000008881 mucosal defense Effects 0.000 description 1
• 230000004678 mucosal integrity Effects 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 210000002464 muscle smooth vascular Anatomy 0.000 description 1
• 210000001087 myotubule Anatomy 0.000 description 1
• AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
• DYGBNAYFDZEYBA-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-n-[(4-oxo-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(CC(=O)N(CC2CC2)CC=2NC(=O)C=3COCCC=3N=2)CC1 DYGBNAYFDZEYBA-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 230000010004 neural pathway Effects 0.000 description 1
• 210000003757 neuroblast Anatomy 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 230000006576 neuronal survival Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 239000002840 nitric oxide donor Substances 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 238000001151 non-parametric statistical test Methods 0.000 description 1
• 208000029552 nuclear cataract Diseases 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 208000015380 nutritional deficiency disease Diseases 0.000 description 1
• QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000008182 oocyte development Effects 0.000 description 1
• 230000034004 oogenesis Effects 0.000 description 1
• 210000004273 ophthalmic nerve Anatomy 0.000 description 1
• 210000002985 organ of corti Anatomy 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 230000010355 oscillation Effects 0.000 description 1
• 230000004072 osteoblast differentiation Effects 0.000 description 1
• 210000004409 osteocyte Anatomy 0.000 description 1
• 208000005368 osteomalacia Diseases 0.000 description 1
• 230000003642 osteotropic effect Effects 0.000 description 1
• 229940127084 other anti-cancer agent Drugs 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 210000000277 pancreatic duct Anatomy 0.000 description 1
• 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
• 208000021255 pancreatic insulinoma Diseases 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 210000002990 parathyroid gland Anatomy 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 238000012402 patch clamp technique Methods 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 210000003899 penis Anatomy 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 210000004049 perilymph Anatomy 0.000 description 1
• 201000001245 periodontitis Diseases 0.000 description 1
• 230000036972 phasic contraction Effects 0.000 description 1
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
• 229960003424 phenylacetic acid Drugs 0.000 description 1
• 239000003279 phenylacetic acid Substances 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 235000008729 phenylalanine Nutrition 0.000 description 1
• 229960005190 phenylalanine Drugs 0.000 description 1
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
• 239000002644 phorbol ester Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 208000014321 polymorphic ventricular tachycardia Diseases 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 238000011533 pre-incubation Methods 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 108090000468 progesterone receptors Proteins 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 230000001902 propagating effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 244000000040 protozoan parasite Species 0.000 description 1
• 230000000722 protumoral effect Effects 0.000 description 1
• 210000001147 pulmonary artery Anatomy 0.000 description 1
• 238000007388 punch biopsy Methods 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 229940076788 pyruvate Drugs 0.000 description 1
• 238000000718 qrs complex Methods 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 239000012048 reactive intermediate Substances 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000029865 regulation of blood pressure Effects 0.000 description 1
• 230000021014 regulation of cell growth Effects 0.000 description 1
• 230000018406 regulation of metabolic process Effects 0.000 description 1
• 230000025160 regulation of secretion Effects 0.000 description 1
• 230000003014 reinforcing effect Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 210000001995 reticulocyte Anatomy 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 208000007442 rickets Diseases 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 239000004576 sand Substances 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000009758 senescence Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 description 1
• 230000008054 signal transmission Effects 0.000 description 1
• 230000007727 signaling mechanism Effects 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 210000001013 sinoatrial node Anatomy 0.000 description 1
• 210000001626 skin fibroblast Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229940083618 sodium nitroprusside Drugs 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 230000021595 spermatogenesis Effects 0.000 description 1
• 238000003153 stable transfection Methods 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 239000010959 steel Substances 0.000 description 1
• 230000000365 steroidogenetic effect Effects 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000003107 substituted aryl group Chemical group 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 210000000221 suprachiasmatic nucleus Anatomy 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000003956 synaptic plasticity Effects 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 239000008399 tap water Substances 0.000 description 1
• 235000020679 tap water Nutrition 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 210000000779 thoracic wall Anatomy 0.000 description 1
• 201000005060 thrombophlebitis Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 210000002303 tibia Anatomy 0.000 description 1
• 230000030968 tissue homeostasis Effects 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 230000032895 transmembrane transport Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 210000001364 upper extremity Anatomy 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 210000005167 vascular cell Anatomy 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 230000001457 vasomotor Effects 0.000 description 1
• 230000001720 vestibular Effects 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 230000037314 wound repair Effects 0.000 description 1
• 210000002417 xiphoid bone Anatomy 0.000 description 1
• 239000001043 yellow dye Substances 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1